Kinfo
Armata Pharmaceuticals Inc. logo

Armata Pharmaceuticals Inc.

ARMPNYSEHealthcare·US · USD
$6.46
-0.94 (-12.70%)
Close · 2026-06-29

Price

Key statistics

Valuation
Market cap237.15M USD
Enterprise value640.58M USD
Trailing P/E-1.34
Forward P/E-4.71
PEG ratio-0.00
Price / sales52.22
Price / book-0.76
Profitability
Gross margin0.00%
Operating margin-1113.44%
Profit margin0.00%
Return on assets-25.32%
Return on equity79.51%
Income (TTM)
Revenue5.20M USD
Gross profit-11.20M USD
EBITDA-30.20M USD
Net income-282.61M USD
Diluted EPS-$7.78
Rev. growth (YoY)60.70%
Balance sheet
Total cash4.75M USD
Total debt373.67M USD
Debt / equity-1.20
Current ratio0.64
Book value / share-$8.50
Cash flow (TTM)
Operating cash flow-23.96M USD
Levered free cash flow-25.84M USD
Shares & price
Shares outstanding36.64M
Float11.55M
Held by institutions10.46%
Beta1.23
50-day MA$8.82
200-day MA$7.32
52-week high$16.34
52-week low$1.85
Dividends
Forward rate
$0.00
Yield
0.00%
Payout ratio
0.00%
Frequency
Unknown
Earnings (EPS)
DateEst.ActualSurprise2026-05-13-0.38-3.16−731.58%2026-03-24-0.40-1.00−150.00%2026-02-230.420.40−4.76%2026-01-231.611.87+16.15%
About Armata Pharmaceuticals Inc.

Armata Pharmaceuticals Inc. is a biotechnology company dedicated to the development of innovative therapies to treat antibiotic-resistant infections. Operating in the healthcare sector, the company focuses on bacteriophage-based solutions, aiming to address the growing global issue of antimicrobial resistance. Armata Pharmaceuticals specializes in researching and developing treatments derived from natural phages, viruses that specifically target and eliminate bacteria, offering an alternative to traditional antibiotics. The company’s efforts are crucial in fields impacted by resistant bacterial strains, including healthcare-associated infections and chronic illnesses linked to bacterial biofilms. With its headquarters in the United States, Armata engages in collaborations with various research institutions and industry partners, emphasizing a scientific approach alongside cutting-edge technology. Armata Pharmaceuticals holds a significant position in the biopharmaceutical market, contributing to the advancement of precision medicine and public health innovations. Its dedication to addressing unmet medical needs positions it as a key player in the development of next-generation antimicrobial therapies. By exploring bacteriophage technology, Armata aims to provide targeted, effective alternatives that could revolutionize how infections are managed globally.

Sector
Healthcare
Industry
Biotechnology
CEO
Dr. Deborah L. Birx M.D.
Employees
60
Headquarters
Los Angeles, CA, United States

Frequently asked questions about Armata Pharmaceuticals Inc.